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Abstract Concerns have been raised regarding sub-opti-
mal utilization of analgesics and psychotropic drugs in the
treatment of patients with chronic musculoskeletal disor-
ders (MSDs) and their associated co-morbidities. The
objective of this study was to describe drug prescriptions
for the management of spinal and non-spinal MSDs con-
trasted against a standardized measure of quality of life. A
representative population sample of 1,756 MSDs patients
[38.5% with spinal disorder (SD) and 61.5% with non-
spinal MSDs (NS-MSD)] was drawn from the EPI3-
LASER survey of 825 general practitioners (GPs) in
France. Physicians recorded their diagnoses and prescrip-
tions on that day. Patients provided information on socio-
demographics, lifestyle and quality of life using the Short
Form 12 (SF-12) questionnaire. Chronicity of MSDs was
defined as more than 12 weeks duration of the current
episode. Chronic SD and NS-MSD patients were pre-
scribed less analgesics and non-steroidal anti-inflammatory
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drugs than their non-chronic counterpart [odds ratios (OR)
and 95% confidence intervals (CI), respectively: 0.4,
0.2–0.7 and 0.5, 0.3–0.6]. They also had more anxio-
depressive co-morbidities reported by their physicians (SD:
16.1 vs.7.4%; NS-MSD: 21.6 vs. 9.5%) who prescribed
more antidepressants and anxiolytics with a difference that
was statistically significant only for spinal disorder patients
(OR, 95% CI: 2.0, 1.1–3.6). Psychotropic drugs were more
often prescribed in patients in the lower quartile of SF-12
mental score and prescriptions of analgesics in the lower
quartile of SF-12 physical score (P \ 0.001). In conclu-
sion, anxiety and depressive disorders were commonly
reported by GPs among chronic MSD patients. Their
prescriptions of psychotropic and analgesic drugs were
consistent with patients’ self-rated mental and physical
health.
Keywords Spinal disorders  Musculoskeletal disorders 
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Introduction
Physicians in primary care play a central role in the man-
agement of musculoskeletal disorders (MSDs). In France,
as in most industrialized countries, they represent one of
the most frequent reasons for consultation [1]. Clinical
guidelines emphasize the treatment of pain and inflam-
mation in the acute phase with gradual recourse to stronger
analgesia and the management of psychological impacts as
the condition evolves toward chronicity. In this context,
concerns have been raised regarding sub-optimal use of
analgesics and psychotropic drugs (antidepressants) in the
treatment of patients with chronic MSDs [2, 3]. This issue
has been examined by comparing guidelines with actual
practice in benchmarking approaches [4, 5]. The goal of
this study was to describe physician’s prescriptions for the
management of acute and chronic MSDs in a large popu-
lation of patients seen in primary care, and examine the
pertinence of prescriptions against patient’s self-assessed
quality of life.
Materials and methods
Study design and population
The EPI3-LASER study was a nation-wide observational
survey of a representative sample of general practitioners
(GPs) and their patients, conducted in France between
March 2007 and July 2008. Its aims were to assess the
burden of disease in general practice, considering physician
and patients characteristics, co-morbidities and prescrip-
tions with a specific focus on health-related quality of life.
The study population was drawn from a two-stage
sampling. First, GPs were randomly selected from the
French national directory of physicians and invited to
participate, which meant allowing a research assistant to be
in the patients’ waiting room for a 1-day consultation
session, collecting basic information on all patients con-
sulting that day and recruiting volunteers to fill out a self-
administered questionnaire. The second stage consisted of
randomly sampling the 1-day of consultation for each
participating physician to survey all patients attending the
practice on that specific day. GPs sampling was stratified to
take into account the diversity of practices (strict conven-
tional medicine and use of homeopathy and other com-
plementary medicines).
All patients were eligible for inclusion to the exception
of those whose health status or literacy level did not allow
responding to a self-administered questionnaire. On the day
selected for patients inclusion, a trained interviewer
recruited on site, in the waiting room, all consecutive eli-
gible patients up to a maximum of 15. Consenting patients
completed a self-administered questionnaire that included
information on age, gender, education, employment status
and occupation, type of health insurance, hospitalization
and medical visits in the previous 12 months, smoking,
alcohol intake, physical activity, height and weight, and
health related quality of life assessed by the Short Form 12
(SF-12) questionnaire [6–8].
GPs completed a medical questionnaire including the
main reason for consultation and up to five other diagnoses
present that day and for each, the duration of the health
problem in its current episode. No diagnostic criteria was
provided in this survey. GPs reported their diagnoses as
they normally do it in their usual practice. GPs also
recorded their prescriptions that day for diagnostic tests,
drugs and referrals. Diagnoses were coded by a trained
archivist using the 9th revision of the International Clas-
sification of Diseases. In this analysis adult patients
18 years and older with a MSD as their main reason for
consultation were included. MSDs were classified as spinal
disorders (SD) with ICD codes 720–724, and non-spinal
MSDs (NS-MSD), such as osteoarthritis and tendonitis of
the upper or lower limb, with ICD codes 715, 719, 729,
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726–728, 782. Patients with a diagnosis of inflammatory,
infectious or neoplastic joint disease as their main reason
for consultation were excluded from the analyses. SD and
NS-MSD were classified as acute–subacute or chronic
using a 12-week (3 months) cut-off for duration of symp-
toms in the current episode in accordance with consensus
recommendations for research on SD [9]. Patients, inter-
viewers and physicians were blind to the specific objectives
of this analysis.
Statistical analysis
Characteristics of non-participating patients (gender, age,
length of time attending the GPs’ practice, type of health
insurance and main reason for consultation) were used to
calibrate the final sample so that it represented more clo-
sely the whole study population, using a procedure known
in demographic studies as the CALMAR procedure [10].
Factors associated with chronicity were identified in mul-
tiple logistic regression analyses. Odds ratios were calcu-
lated for the comparison of prescriptions between chronic
and non-chronic patients using mixed models accounting
for a random physician effect (GLIMMIX and NLMIXED
procedures in SAS). Mean scores of the SF-12 mental and
physical scales were adjusted for gender, age and co-
morbidities using the analysis of covariance. Tests for trend
on proportions of medication users by quartile of the SF-12
subscales were performed using the Cochrane–Armitage
test for trend. All analyses were performed using SAS
version 9.1.
The study was approved by the French National Data-
Protection Commission (CNIL) and the French National
Council of Physicians (CNOM). Participating physicians
received compensation fees but not patients.
Results
Of the 17,206 GPs randomly selected and invited by mail
to participate, 825 agreed to participate in the study. Their
geographical distribution covered the 22 regions of France.
Their median age was 52 years, 23.5% were female, 51.8%
worked in solo practice and 7.6% practiced fee-for-service
in addition to the general health insurance regime. The
median number of patients recruited at each physicians’
office was two with 11.2% recruiting five or more. Of the
10,803 patients identified as potential participants, 2,151
(19.9%) declined participation and 93 were excluded
because of missing information leaving a final sample of
8,559, of whom 665 (7.8%) had a SD as their main reason
for consultation, and 1,027 (12.0%) a NS-MSD (Table 1).
They were female in proportions of 59.0 and 61.6% for SD
and NS-MSD, respectively, and SD patients were younger
by 8.2 years on average. The proportion who had their
problem for 12 weeks or more at the time of consultation
were respectively 43.0 and 58.5% for SD and NS-MSD.
Factors associated with chronicity of SD were age, with the
largest proportion observed over the age of 60 [odds ratio
(OR): 4.5, 95% confidence interval (CI): 2.1–9.6], and not
being employed (OR = 2.0, 95%: 1.1–3.6). For NS-MSD,
factors associated with chronicity were female gender
(OR = 1.7, 95% CI: 1.2–2.3) and age (OR for patients 60
and over = 2.3, 95% CI: 1.2–4.4). Physician’s character-
istics (sex, age and fee-for-service practice) were not
associated with chronicity.
Physicians declared about twice as much MSD co-
morbidities (at least one secondary MSD diagnosis) for
their chronic patients than their acute–subacute patients
(Table 2). After controlling for age and gender, the odds
ratio of having a MSD co-morbidity in chronic SD patients
was 2.4 (95% CI: 1.5–4.0) and in chronic NS-MSD
patients, 1.7 (95% CI: 1.1–2.7). Chronic patients also had
about twice as much anxiety, depressive and sleeping
disorders diagnoses than their acute–subacute counterpart
with odds ratios respectively in SD and NS-MSD patients
of 1.9 (95% CI: 1.2–2.9) and 2.0 (95% CI: 1.5–2.8). Dif-
ferences between acute–subacute and chronic patients for
digestive co-morbidities were not statistically significant
but an excess cardiovascular disorders was observed in
chronic NS-MSD patients (OR = 1.5, 95% CI: 1.1–1.9)
which was essentially explained by a four times higher
number of hypertensive patients compared to their acute–
subacute counterpart (16 against 4).
Quality of life scores (SF12) were almost identical
between SD and NS-MSD patients. Chronic SD patients
had a physical mean score adjusted for age, gender and co-
morbidities, 2.4 points lower than acute–subacute patients
(P = 0.001), while their mental scores were almost iden-
tical. The reverse was observed in NS-MSD patients where
the difference was observed in the mental scale with a
difference of 1.7 points lower among chronic patients
(P = 0.004).
Chronic SD and NS-MSD patients received half the
analgesics, non-steroidal anti-inflammatory drugs (NSA-
IDs) and muscle relaxants prescriptions than their acute–
subacute counterpart after controlling for co-morbidities
and other confounding factors [Table 3, OR = 0.4 (95%
CI: 0.2–0.7) and 0.5 (95% CI: 0.3–0.6), respectively, sta-
tistically significant]. The reverse was observed for anti-
depressants, anxiolytics and hypnotics with almost twice
more prescriptions in chronic SD patients (OR = 2.0, 95%
CI: 1.1–3.6) but not in NS-MSD patients (OR = 1.3, 95%
CI: 0.8–2.1). For non-pharmacological prescriptions,
imaging was almost twice as much prescribed in acute–
subacute than chronic patients but there was no statistical
difference with referral to physiotherapy or to a specialist.
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Frequencies of prescription of analgesics and of psy-
chotropic drugs (antidepressant, anxiolytic and hypnotic
drugs combined) in all chronic patients (SD and NS-
MSD), were computed by SF-12 mental and physical
scores (Table 4). Two statistically significant trends were
found, one for psychotropic drugs increasing with a
decreasing (worsening) mental score, and the other for
analgesic drugs increasing with decreasing (worsening)
physical score. Similar trends were observed with phy-
sicians reporting of MSD and anxio-depressive co-mor-
bidities but reached statistical significance only in the
former. It is noteworthy that among chronic patients in
the lower decile of SF-12 mental score (not shown in
Table 4), 42.2% (38/91) were prescribed a psychotropic
drug.
Discussion
Physicians’ participation to this survey was low in part due
to the important intrusive nature of the study into their
practice. We found no equivalent in the scientific literature
for a study of this size and the large population of patients
was nevertheless representative of the French population
consulting a GP. First, the distribution of GPs individual
characteristics differed from published national statistics
only for gender with 23.5% female in the Epi3 survey
versus 39% in all of France for the year 2008 [11]. This
difference had potentially little impact on patients’ results
as physicians’ characteristics were not associated with
chronicity in our analyses. In addition, patients’ non par-
ticipation was partially controlled by a weighting
Table 1 Socio-demographic characteristics of patients with musculoskeletal disorders (MSD) in primary care (N = 1,692)
Spinal disorders Non-spinal MSD (upper and lower limb)
Total B12 weeks [12 weeks Total B12 weeks [12 weeks
N = 665 N = 376 N = 289 N = 1027 N = 404 N = 623
Gender of patients (% Female) 59.0 57.1 62.1 61.6 51.9* 69.2*
Age of patients (mean, SD) 49.6 (14.1) 47.0* (14.3) 53.7* (13.2) 57.9 (15.2) 53.3* (16.6) 61.5* (13.2)
Employment status (%)
Employed 58.4 64.8* 48.2* 38.6 46.8 32.2
On unemployment benefits 3.0 3.0 2.8 2.9 2.6 3.1
Home maker 3.2 2.2 5.0 3.5 2.7 4.0
Student 2.5 3.1 1.6 2.0 3.5 0.9
Retired, other unemployed 31.3 25.2 40.8 52.3 43.5 59.2
Education (% completed high school) 43.3 48.9 33.9 35.2 44.9 27.6
Familial status (%)
Living with a spouse 69.3 69.8 68.6 64.9 66.6 63.4
Living with children 44.3 45.3 43.0 30.7 32.7 29.2
Body mass index (%)
0–24 49.1 51.2 45.9 45.1 48.9 42.1
25–29 37.3 35.4 40.4 34.3 33.9 34.6
30 and over 11.9 11.6 12.3 19.7 17.1 21.8
Tobacco consumption (%)
Never smoked 44.8 44.6 44.8 53.0 49.8 55.5
Past smoker 25.4 23.7 28.1 25.5 25.2 25.7
Current smoker 29.5 31.3 26.9 21.4 25.0 18.7
Alcohol consumption (%)
Never 33.9 30.5 39.8 32.3 31.5 32.8
Sometimes 56.3 57.9 53.7 49.7 50.4 49.2
Daily 9.3 10.9 6.4 17.9 18.1 17.7
Physical exercise (%)
0–30 min per day 59.2 61.1 56.0 58.8 54.6 62.1
31 min and over 38.3 35.9 42.3 39.6 44.2 36.0
Physician visit previous 12 months
Yes 96.0 95.3 97.1 96.4 95.0 97.5
* Comparison B12 weeks, [12 weeks statistically significant (P \ 0.05) in multiple logistic regression including all variables in the table
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procedure based on socio-demographic information col-
lected on non-respondents at recruitment. Secondly, SF-12
scores observed in our study were not far away from those
reported in three European population surveys of patients
with MSDs, and score differences between acute and
chronic patients were also similar [12, 13]. Finally,
Table 2 Co-morbidities and quality of life in patients with musculoskeletal disorders (MSD) in primary care (N = 1,692)
Co-morbidities present at the medical visit Spinal disorders Non-spinal MSD (upper and lower limb)
Total B12 weeks [12 weeks Total B12 weeks [12 weeks
N = 665 N = 376 N = 289 N = 1027 N = 404 N = 623
MSD co-morbidities (%) 11.6 8.3* 16.9* 7.6 5.8* 8.9*
Other co-morbidities (%)a
At least one 32.3 26.8* 41.1* 56.1 40.9* 68.0*
Anxio-depressive disorders 10.7 7.4* 16.1* 16.3 9.5* 21.6*
Sleeping disorders 2.7 1.3* 5.0* 5.1 3.7* 6.2*
Cardiovascular–respiratory 19.3 18.0 21.1 37.2 25.4* 46.4*
Digestive disorders 6.1 7.0 4.4 8.8 5.8 11.1
Quality of life SF-12b
Mental score mean (SD) 39.9 (1.2) 40.8 (2.0) 40.5 (2.0) 40.6 (1.1) 41.5* (1.6) 39.8* (1.4)
Physical score mean (SD) 42.2 (1.3) 42.0* (2.2) 39.6* (2.2) 42.7 (1.2) 44.0 (1.6) 43.1 (1.4)
* Comparison B12 and [12 weeks: P \ 0.01
a ICD-9 codes for anxio-depressive disorders: 300–316, 799; sleeping disorders: 780; cardiovascular: 415–426, 428–448, 785; respiratory:
472–474, 476–477, 490–496; digestive: 520–537, 540–553, 555–558, 560–579, 787, 789
b Mean adjusted for age, gender and presence of co-morbidities
Table 3 Prescriptions at the medical visit in patients with musculoskeletal disorders (MSD) in primary care (N = 1,692)
Spinal disorders Non-spinal MSD (upper and lower limb)
Total B12 weeks [12 weeks Total B12 weeks [12 weeks
N = 665 N = 376 N = 289 N = 1027 N = 404 N = 623
At least one (%)
Analgesics 56.8 61.5 49.1 45.3 50.5 41.4
NSAID (without aspirin) 40.9 45.7 33.5 30.2 41.4 21.4
Muscle relaxants 31.1 38.0 20.0 5.8 7.1 4.8
Anti-osteoarthritis drugs 0.4 0.2 0.6 5.8 1.9 8.9
[12 versus B12 weeks OR (95% CI)* 1.0 (–) 0.4 (0.2–0.7) 1.0 (–) 0.5 (0.3–0.6)
At least one (%)
Antidepressants 7.5 4.6 12.1 8.9 4.3 12.5
Anxiolytics 5.0 3.9 6.9 9.0 5.8 11.6
Hypnotics 3.4 1.7 6.1 6.6 4.5 8.3
[12 versus B 12 weeks OR (95% CI)* 1.0 (–) 2.0 (1.1–3.6) 1.0 (–) 1.3 (0.8–2.1)
A least one (%)
Imaging (X-rays, CT scan or MRI) 16.2 19.9 10.3 14.2 18.5 10.9
Lab tests 11.2 12.0 9.9 13.2 10.9 15.0
[12 versus B12 weeks OR (95% CI)* 1.0 (–) 0.4 (0.3–0.8) 1.0 (–) 0.7 (0.5–1.0)
A least one (%)
Physiotherapy 17.6 17.8 17.3 13.6 13.4 13.8
Reference to a specialist 9.1 6.6 13.2 17.6 15.1 19.7
[12 versus B12 weeks OR (95% CI)* 1.0 (–) 0.9 (0.6–1.4) 1.0 (–) 1.0 (0.7–1.4)
* Odds ratios and 95% confidence intervals derived from multivariate mixed regression models adjusting for all variables in Tables 1 and 2 and
for physician’s effect
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NSAIDs utilization was close to what has been observed in
two other studies but our frequency of prescription of
antidepressants was about half [2–14]. Prescription of
physiotherapy was also lower than what has been reported
in another French survey [15]. Differences could be
attributed to the cross-sectional nature of the surveys, dif-
ferences in sources of information and type of insurance
coverage of the patients.
The impact of chronicity on quality of life, co-morbid-
ities and prescriptions was similar between SD and NS-
MSD patients. Our study showed that drug prescription in
primary care was well correlated to physical and mental
patient’s self-assessed quality of life, using a standardized
instrument independent from the clinician’s evaluation.
The neat gradient of prescription of psychotropic drugs
with the mental scale and of analgesics with the physical
scale of the SF-12, provided evidence of the pertinence of
physician’s prescriptions. For instance, chronic MSD
patients were twice as likely to have anxio-depressive and
sleeping disorders, a burden that has been raised in sys-
tematic reviews [16, 17]. The concomitant presence of
chronic pain and anxio-depressive disorders has been at the
source of confusion in the scientific literature on efficacy of
antidepressants against chronic pain [18, 19]. Our results
indicated that clinicians seemed able to adapt their pre-
scription to the pain and psychological components for
their chronic pain patients.
Our results showed that over 50% of chronic patients
with a very low mental score (lower decile) received no
prescription for a psychotropic drug. This is not in
contradiction, however, with recent evidence that indicates
limited or no benefit of antidepressant drugs in populations
with mild or moderate symptoms, which would account for
a significant proportion of chronic pain patients [20].
The prevalence of sleeping problems was low compared
to what has been reported in a systematic review on that
topic but data remains sparse on this topic [16]. Sleeping
disorders have been associated to pain intensity but not to
duration (chronicity) of symptoms which is the marker
usually cited in clinical guidelines. Anxio-depressive
symptoms and sleeping quality should be a systematic part
of the medical questionnaire with chronic MSD patients
because of their impact on quality of life.
The high hypertension and digestive disorders observed
in patients consulting for MSDs in primary care has been
reported in another study and was partly explained by age
[13]. The higher, but not statistically significant, digestive
co-morbidities observed in chronic compared to acute–
subacute NS-MSD patients might explain the lower pre-
scription of NSAIDs in that group [21].
The main limitation of this study was the cross-sectional
nature of data collection and analyses. Associations found
between quality of life and prescriptions for instance, cannot
be interpreted as causally linked. Prescriptions of the day was
a mix of new prescriptions and renewals and represented the
patients’ status at one point in time. Because patients
responded to the SF-12 questionnaire before they saw their
physician in consultation, there is a possibility that this had
influenced physicians’ diagnoses and prescriptions. Two
elements contributed to minimize this effect if it existed.
First, the scoring procedure used to derive mental and
physical scores from responses to the SF-12 questionnaire,
was not known from patients. Secondly, the SF-12 ques-
tionnaire was included in a general questionnaire on health
that did not focus on any specific health issue.
Another limitation was the declarative nature of diag-
noses and prescriptions provided by participating physi-
cians. No diagnostic criteria was suggested for reporting
MSDs diagnoses ore anxio-depressive co-morbidities. This
was a deliberate choice in order to describe clinical prac-
tice in real life situation. We feel confident that the large
number of participating physicians and patients contributed
to the overall representativity of clinical practice in pri-
mary care in France. In addition, MSD patients were
identified from a large sample of patients consulting for
any reason in primary care, thus minimizing biases related
to sampling MSD patients directly. The main strength of
the study was the combination of medical information on
diagnoses and prescriptions on one hand, and patients’
information on quality of life on the other hand, both
collected on the day of consultation insuring timely
compatibility.
Table 4 Analgesic and psychotropic drugs prescription in patients
with MSDs of more than 12 weeks duration by quality of life quar-
tiles (N = 911)
* Test for trend: P \ 0.001
a Antidepressants, anxiolytics and hypnotics
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Conclusion
In conclusion, important differences were observed in the
clinical management of acute–subacute and chronic MSD
French patients in primary care. Anxiety and depressive
disorders were commonly reported by GPs among chronic
MSD patients. GPs’ prescriptions of psychotropic and
analgesic drugs seemed pertinent as they were consistent
with a standardized measure of quality of life, independent
from the clinicians’ judgement. This utilization of patients’
self-assessed quality of life provided a useful benchmark-
ing approach to assess consistency between clinical prac-
tice and guidelines.
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